Figure 1. Odds Ratios of Intracranial Hemorrhage With Use of Individual Non–Vitamin K Antagonist Oral Anticoagulants (NOACs) vs Aspirin, by Trial and Pooled.

This figure presents odds ratios of intracranial hemorrhage of individual NOACs vs aspirin, by trial and pooled, calculated via the Mantel-Haenszel method. AVERROES indicates Apixaban Vs Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment; COMPASS, Cardiovascular Outcomes for People Using Anticoagulation Strategies; EINSTEIN CHOICE, Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism; NAVIGATE ESUS, Rivaroxaban Vs Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source.